Economic implications of extended-release metoprolol succinate for heart failure in the MERIT-HF trial: a US perspective of the MERIT-HF trial.

[1]  S. Gottlieb,et al.  Efficacy, safety and tolerability of β-adrenergic blockade with metoprolol CR/XL in elderly patients with heart failure , 2004 .

[2]  R. Califf,et al.  Economic effects of beta-blocker therapy in patients with heart failure. , 2004, The American journal of medicine.

[3]  J. O'brien,et al.  MH3 HOSPITALIZATION RELATED TO ABUSE OF THE ELDERLY WITH DEMENTIA AND OTHER MENTAL HEALTH DISORDERS: RESOURCE USE AND COSTS , 2003 .

[4]  A. Jánosi,et al.  Metoprolol CR/XL in postmyocardial infarction patients with chronic heart failure: experiences from MERIT-HF. , 2003, American heart journal.

[5]  D. DeMets,et al.  Effect of Carvedilol on the Morbidity of Patients With Severe Chronic Heart Failure: Results of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study , 2002, Circulation.

[6]  I. Piña,et al.  Metoprolol CR/XL in Female Patients With Heart Failure: Analysis of the Experience in Metoprolol Extended-Release Randomized Intervention Trial in Heart Failure (MERIT-HF) , 2002, Circulation.

[7]  M. Fisher,et al.  Tolerability of &bgr;-Blocker Initiation and Titration in the Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF) , 2002, Circulation.

[8]  G. Thorgeirsson,et al.  Effects of metoprolol CR/XL on mortality and hospitalizations in patients with heart failure and history of hypertension. , 2002, Journal of cardiac failure.

[9]  C. O'connor,et al.  The benefit of implementing a heart failure disease management program. , 2001, Archives of internal medicine.

[10]  B. Fagerberg,et al.  Metoprolol controlled release/extended release in patients with severe heart failure: analysis of the experience in the MERIT-HF study. , 2001, Journal of the American College of Cardiology.

[11]  H Wedel,et al.  Challenges of subgroup analyses in multinational clinical trials: experiences from the MERIT-HF trial. , 2001, American heart journal.

[12]  B. O'brien,et al.  Cost-effectiveness of beta-blocker therapy with metoprolol or with carvedilol for treatment of heart failure in Canada. , 2001, American heart journal.

[13]  G. Oster,et al.  Cost-Effectiveness Results from the US Carvedilol Heart Failure Trials Program , 2001, The Annals of pharmacotherapy.

[14]  A. Mcguire.  Reduced costs with bisoprolol treatment for heart failure: an economic analysis of the second Cardiac Insufficiency Bisoprolol Study (CIBIS-II). , 2001, European heart journal.

[15]  S. Varney.  A cost‐effectiveness analysis of bisoprolol for heart failure , 2001, European journal of heart failure.

[16]  D. DeMets,et al.  Effect of carvedilol on survival in severe chronic heart failure. , 2001, The New England journal of medicine.

[17]  M. Konstam,et al.  Economic impact of beta blockade in heart failure. , 2001, The American journal of medicine.

[18]  G. Oster,et al.  Influence of carvedilol on hospitalizations in heart failure: incidence, resource utilization and costs. U.S. Carvedilol Heart Failure Study Group. , 2001, Journal of the American College of Cardiology.

[19]  John Wikstrand,et al.  Effects of Controlled-Release Metoprolol on Total Mortality, Hospitalizations, and Well-being in Patients with Heart Failure: The Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF) , 2000 .

[20]  R Dietz,et al.  Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group. , 2000, JAMA.

[21]  Fach,et al.  Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in-Congestive Heart Failure (MERIT-HF) , 1999, The Lancet.

[22]  G. Oster,et al.  Cost effectiveness of carvedilol for heart failure. , 1999, The American journal of cardiology.

[23]  Sheldon Howard Jacobson,et al.  Application of discrete-event simulation in health care clinics: A survey , 1999, J. Oper. Res. Soc..

[24]  CIBIS-II Investigators and Committees.  The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial , 1999, The Lancet.

[25]  J Karnon,et al.  Selecting a decision model for economic evaluation: a case study and review , 1998, Health care management science.

[26]  C. Fahrenbruch,et al.  Circadian variations in the occurrence of cardiac arrests: initial and repeat episodes. , 1998, Circulation.

[27]  Jackson Cb,et al.  Physicians' Current Procedural Terminology. , 1973 .

[28]  P. Deedwania,et al.  Efficacy, safety and tolerability of metoprolol CR/XL in patients with diabetes and chronic heart failure: experiences from MERIT-HF. , 2005, American heart journal.

[29]  J. Wikstrand,et al.  MERIT-HF – description of the trial , 2000, Basic Research in Cardiology.

[30]  B. Fagerberg,et al.  MERIT-HF mortality and morbidity data , 2000, Basic Research in Cardiology.

[31]  Averill M. Law,et al.  Simulation Modeling and Analysis , 1982 .